Trial · NCT01638000
Results by group1,626
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,626
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours | Mirabegron 50 mg | -2.95 | Standard Error 0.087 | micturitions | |
| Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours | Solifenacin 5 mg | -3.13 | Standard Error 0.088 | micturitions | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Mirabegron 50 mg | Overall | 5 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Solifenacin 5 mg | Overall | 7.4 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Mirabegron 50 mg | Dry mouth | 3.1 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Solifenacin 5 mg | Dry mouth | 5.8 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Mirabegron 50 mg | Dry throat | 0.1 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Solifenacin 5 mg | Dry throat | 0.1 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Mirabegron 50 mg | Blurred vision | 0.6 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Solifenacin 5 mg | Blurred vision | 0.4 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Mirabegron 50 mg | Constipation | 2.2 | percentage of participants | |
| Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period | Solifenacin 5 mg | Constipation | 2.5 | percentage of participants | |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Mirabegron 50 mg | Week 4 [N=916,906] | -2.37 | Standard Error 0.083 | micturitions |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Solifenacin 5 mg | Week 4 [N=916,906] | -2.33 | Standard Error 0.083 | micturitions |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Mirabegron 50 mg | Week 8 [N=888,876] | -2.77 | Standard Error 0.084 | micturitions |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Solifenacin 5 mg | Week 8 [N=888,876] | -3.00 | Standard Error 0.085 | micturitions |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Mirabegron 50 mg | Week 12 [N=870,856] | -3.02 | Standard Error 0.088 | micturitions |
| Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours | Solifenacin 5 mg | Week 12 [N=870,856] | -3.21 | Standard Error 0.089 | micturitions |
| Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit | Mirabegron 50 mg | Week 4 [N=404,410] | 2.64 | Standard Error 0.280 | incontinence episodes |
| Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit | Solifenacin 5 mg | Week 4 [N=404,410] | 2.25 | Standard Error 0.217 | incontinence episodes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01638000/results